Barclays maintains an 'Equalweight' rating on Nektar Therapeutics (NASDAQ: NKTR), PT $14.

Barclays analyst says, "Yesterday, Nektar announced positive detailed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE